Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07779018) titled 'CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy' on Aug. 19.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Liping Dou

Condition: Lymphoma

Intervention: Drug: CD22/CD19 CAR-T cell immunotherapy

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: April 1, 2026

Target Sample Size: 30

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07779018

Disclaimer: Curated by HT Syndicatio...